In an investigation of the mechanisms of the neuroprotective eŠects of theanine (g-glutamylethylamide) in brain ischemia, inhibition by theanine of the binding of [ 3 H](RS )-a-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA), [ 3 H]kainate, and [ 3 H]( E )-3-(2-phenyl-2-carboxyethenyl)-4,6-dichloro-1-H-indole-2-carboxylic acid (MDL 105,519) to glutamate receptors was studied in terms of its possible inhibiting eŠects on the three receptor subtypes (AMPA, kainate, and NMDA glycine), with rat cortical neurons. Theanine bound the three receptors, but its IC 50 of theanine was 80-to 30,000-fold less than that of L-glutamic acid.
The glutamate-calcium theory has almost been accepted as an explanation of the mechanisms of ischemic neuronal death, in which glutamic acid, an excitatory neurotransmitter, is discharged in excess into the extracellular space by transient ischemia, and acts to excite toxicity. 1, 2) Theanine is an analog of the glutamic acid found in leaves of high-grade Japanese green tea (Camellia sinensis), and we have examined the eŠects of theanine (g-glutamylethylamide) on glutamate receptors, and the possibility of its protecting against ischemic neuronal death. We earlier found a neuroprotective eŠect of theanine on the neuronal death of hippocampal CA1 neurons in transient forebrain ischemia of gerbils to which theanine was injected into the lateral ventricle before ischemia. 3) In this study, the binding eŠects of theanine on three receptor subtypes, for (RS )-aamino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA), kainate, and N-methyl-D-aspartate (NMDA) receptors, were studied to conˆrm the mechanism of theanine neuroprotection in a radioligand binding assay.
The inhibiting eŠects of theanine on glutamate receptor binding of AMPA, kainate, and the NMDA glycine site antagonist ( E )-3-(2-phenyl-2-carboxyethenyl)-4,6-dichloro-1-H-indole-2-carboxylic acid (MDL 105,519) 4) 8) with the observed IC 50 of the tested compound, the concentration of the radioligand used in the assay, and the historical values for the Kd of the ligand (obtained experimentally at MDS Pharma Services). The Hill coe‹cient, nH, deˆning the slope of the competitive binding curve was calculated with Data Analysis Toolbox. When Hill coe‹cients were signiˆcantly diŠerent from 1.0, the binding displacement may not follow the laws of mass action with a single binding size. Where IC50, Ki, or nH data are presented without the SEM, data are not quantitative, and the values presented should be interpreted with caution. For all receptor binding assays, the percent inhibition was calculated as follows:
(cpm of compound" mean cpm of nonspeciˆcially bound) (mean cpm of total bound" mean cpm of nonspeciˆc bound) ×100 IC 50 and n H were calculated with the Data Analysis Toolbox and nH may be described as follows. Ki is the equilibrium dissociation constant of the competitive inhibitor and was calculated as follows:
Inhibition curves of glutamate receptor subtypes AMPA, kainate, and NMDA glycine were drawn, and the IC50 values were calculated ( Table 1 ). The IC 50 values of theanine were 24.6±0.9 mM for AMPA, 41.5±7.6 mM for kainate, and 347±47 mM for NMDA glycine. The IC50 values of L-glutamic acid were 0.311±0.018 mM for AMPA, 0.537± 0.076 mM for kainate, and 0.011±0.002 mM for NMDA glycine. Thus, theanine bounded with AMPA, kainate, and NMDA receptors, and its binding activity on AMPA and kainate receptors was 10-fold higher than on NMDA glycine receptors. The binding activity of L-glutamic acid with the NMDA glycine receptor was 30-to 50-fold that of AMPA and kainate receptors. The binding activity of theanine on the glutamate receptors subtypes was less than that of L-glutamic acid. The ionic charge of glutamic acid may be important to binding glutamate receptors because theanine is changed to glutamylethylamide by the formation of a complex of Lglutamic acid and ethylamine.
Though the binding activities of theanine on AMPA and kainate receptors were less than those on L-glutamic acid, these IC 50 values were on the order of 10 "5 M, and probably would be useful for neuroprotection in pharmacological uses. The AMPA receptor ordinarily is high permeable to Na + , but not to Ca 2+ . However, the subunit composition of the AMPA receptor may have changed so as to become permeable to Ca 2+ . GluR2 gene expression is lowered, and Ca 2+ ‰ows into cells in the hippocampal CA1 region that shows delayed neuronal death after transient ischemia. 9, 10) These results suggested that theanine also participated in the neuroprotective eŠect by binding to AMPA receptors. Nellgård and Wieloch 11) reported that the antagonists that aŠect the AMPA receptor have a neuroprotective eŠect even when given after ischemia, so theanine administration after ischemia might be useful for neuroprotection.
Pyramidal neurons in the hippocampal CA3 region are susceptible to kainate toxicity, 12) and the binding activity of radiolabelled kainate is the highest at hippocampal CA3 in the brain. 13) Pyramidal neurons in hippocampal CA3 region die after intraperitoneal administration of 8 mg W kg kainate in rats, but this neuronal death is suppressed by intraventricular ad-ministration of theanine before kainate treatment. 14) These results suggested that theanine might participate in the neuroprotective eŠect by binding to the kainate receptor.
The binding of theanine with the NMDA receptors was 30,000-fold less than that of L-glutamic acid in this study. The IC50 of the binding concentration of theanine on NMDA receptors was 10 "4 M, one order of magnitude lower than on AMPA W kainate receptors. However, Nozawa et al. 15) reported that the intracellular Ca 2+ concentration is increased temporarily by exposure to 800 mM theanine in cultured rat cortical neurons. This elevation in the Ca 2+ concentration was inhibited by exposure to 50 mM D-2-amino-5-phosphonopentanoate (D-APV), a competitive NMDA antagonist with a speciˆc ligand. Yokogoshi et al. 16) reported that theanine administration in the brain striatum increases dopamine release, but that theanine-induced dopamine release is inhibited with treatmentˆrst by D-APV. Maruyama and Takeda 17) suggested that theanine is a competitive antagonist on glutamate receptors, but that its binding activity is not as strong. Cotman et al. 13) found that the NMDA receptors have a high density in the hippocampal CA1 region of the brain. We already reported that ischemia-induced delayed neuronal death in the hippocampal CA1 region is prevented in a dose-dependent way by treatment with 250 to 500 mM theanine through the lateral ventricle in the gerbil.
3) These results suggested that there were antagonistic eŠects of theanine on the NMDA receptor providing neuroprotective action, although the binding activity of theanine on NMDA receptors was one of order of magnitude lower than on AMPA W kainate receptors.
Theanine therefore may participate in neuroprotection through its mechanisms of binding to glutamate receptor subtypes (AMPA, kainate, and NMDA receptors), and by blocking the binding to the glutamate receptor of L-glutamic acid discharged in excesse into the extracellular space by cerebral ischemia, leading to neuronal death. However, this was suggested as one of the mechanisms, because the binding activity of theanine on glutamate receptors was lower than that of L-glutamic acid. Theanine is a natural glutamate analog, so it is may not only aŠect glutamate receptors but also may aŠect other mechanisms such as those with glutamate transporters, because glutamic acid discharged in excess into extracellular space is removed by glutamate transporters. 18) Theseˆndings suggest that the inhibiting eŠect of theanine on neuronal death caused by transient brain ischemia is mild, and that the theanine in green tea may useful for prevention of neuronal death.
